2007
Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial
Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial. Journal Of Virology 2007, 82: 1968-1979. PMID: 18057249, PMCID: PMC2258728, DOI: 10.1128/jvi.02343-07.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, ViralAntibody FormationCancer VaccinesCarcinomaCD4-Positive T-LymphocytesDendritic CellsDNA-Binding ProteinsEnzyme-Linked Immunosorbent AssayFemaleHemocyaninsHumansImmunity, CellularNeoplasm StagingOncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus VaccinesRecombinant ProteinsUterine Cervical NeoplasmsVaccinationConceptsCervical cancer patientsIIA cervical cancer patientsDendritic cell vaccinationHuman papillomavirus type 16Cancer patientsDC vaccinationStage IBPapillomavirus type 16Cell vaccinationE7 antigenType 16Delayed-type hypersensitivity reactionEnzyme-linked immunosorbent spotHPV E7 antigenLimited tumor burdenT-cell countsEvidence of diseaseIIA cervical cancerT cell responsesKeyhole limpet hemocyaninEnzyme-linked immunosorbentHPV16/18 E7Vaccine doseAutologous DCsDTH response
2001
Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer
Santin A, Bellone S, Ravaggi A, Roman J, Smith C, Pecorelli S, Cannon M, Parham G. Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2001, 108: 804-808. DOI: 10.1016/s0306-5456(00)00206-0.Peer-Reviewed Original ResearchOvarian cancer patientsAdvanced ovarian cancerIL-10Cancer patientsOvarian cancerAscitic fluidPlasma levelsPeritoneal fluidAdvanced ovarian cancer patientsElevated TGF-β levelsImmunosuppressive cytokine IL-10Anti-tumor immune functionDetectable IL-10Cytokine IL-10TGF-β levelsTime of surgeryDepartment of ObstetricsPlasma samplesNormal female controlsSensitive enzyme-linked immunosorbentEnzyme-linked immunosorbentTGF-β releaseImmunosuppressive cytokinesInterleukin-10Normal control plasma samplesIncreased levels of interleukin‐10 and transforming growth factor‐β in the plasma and ascitic fluid of patients with advanced ovarian cancer
Santin A, Bellone S, Ravaggi A, Roman J, Smith C, Pecorelli S, Cannon M, Parham G. Increased levels of interleukin‐10 and transforming growth factor‐β in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG An International Journal Of Obstetrics & Gynaecology 2001, 108: 804-808. PMID: 11510703, DOI: 10.1111/j.1471-0528.2001.00206.x.Peer-Reviewed Original ResearchConceptsOvarian cancer patientsAdvanced ovarian cancerIL-10Cancer patientsOvarian cancerAscitic fluidPlasma levelsPeritoneal fluidAdvanced ovarian cancer patientsElevated TGF-beta levelsImmunosuppressive cytokine IL-10Anti-tumor immune functionDetectable IL-10TGF-beta levelsCytokine IL-10Time of surgeryDepartment of ObstetricsTGF-beta releasePlasma samplesNormal female controlsSensitive enzyme-linked immunosorbentEnzyme-linked immunosorbentImmunosuppressive cytokinesInterleukin-10Prospective study